Korea spinout Yunovia heads to JPM armed with oral, once-daily GLP-1

Newly spun out Korean biotech Yunovia is aiming to raise about $100 million from investors outside Korea and take a page out of Chinese biotech Eccogene’s playbook by partnering its lead obesity compound, which it believes has advantages over later-stage GLP-1s.

Yunovia Co. Ltd. CEO and CFO JinSik Suh and Chief Business Officer Chae Joon Lee, who is also COO of parent company  Ildong Pharmaceutical Co. Ltd. (KSE:000230), told BioCentury that the South Korea company decided to spin out its R&D division into a new company to focus on its domestic and overseas prescription and OTC businesses, and relieve itself of the expense of pharmaceutical R&D. ...